15 results on '"Bartlett, John M.S."'
Search Results
2. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
- Author
-
Bartlett, John M.S., Ahmed, Ikhlaaq, Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J.H., Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, and Rea, Daniel W.
- Subjects
- *
COMBINED modality therapy , *META-analysis , *MULTIVARIATE analysis , *TAMOXIFEN , *ENDOCRINE system - Abstract
Background A meta-analysis of the effects of HER2 status, specifically within the first 2–3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy or switching strategy tamoxifen followed by AI. The pre-existing standardisation of methodology for HER2 (immunohistochemistry/fluorescence in situ hybridization) facilitates analysis of existing data for this key marker. Methods Following a prospectively designed statistical analysis plan, patient data from 3 phase III trials Arimidex, Tamoxifen, Alone or in Combination Trial (ATAC), Breast International Group (BIG) 1-98 and Tamoxifen Exemestane Adjuvant Multicentre Trial (TEAM)] comparing an AI to tamoxifen during the first 2–3 years of adjuvant endocrine treatment were collected and a treatment-by-marker analysis of distant recurrence-free interval-censored at 2–3 years treatment – for HER2 status × AI versus tamoxifen treatment was performed to address the clinical question relating to efficacy of ‘upfront’ versus ‘switch’ strategies for AIs. Results A prospectively planned, patient-level data meta-analysis across 3 trials demonstrated a significant treatment (AI versus tamoxifen) by marker (HER2) interaction in a multivariate analysis; (interaction hazard ratio [HR] = 1.61, 95% CI 1.01–2.57; p < 0.05). Heterogeneity between trials did not reach statistical significance. The HER2 negative (HER2−ve) group gained greater benefit from AI versus tamoxifen (HR = 0.70, 95% CI 0.56–0.87) than the HER2-positive (HER2+ve) group (HR = 1.13, 95% CI 0.75–1.71). However, the small number of HER2+ve cases (n = 1092 across the 3 trials) and distant recurrences (n = 111) may explain heterogeneity between trials. Conclusions A patient-level data meta-analysis demonstrated a significant interaction between HER2 status and treatment with AI versus tamoxifen in the first 2–3 years of adjuvant endocrine therapy. Patients with HER2−ve cancers experienced improved outcomes (distant relapse) when treated with upfront AI rather than tamoxifen, whilst patients with HER2+ve cancers fared no better or slightly worse in the first 2–3 years. However, the small number of HER2+ve cancers/events may explain a large degree of heterogeneity in the HER2+ve groups across all 3 trials. Other causes, perhaps related to subtle differences between AIs, cannot be excluded and warrant further exploration. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. HER2 testing: Current status and future directions.
- Author
-
Perez, Edith A., Cortés, Javier, Gonzalez-Angulo, Ana Maria, and Bartlett, John M.S.
- Abstract
Abstract: Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for optimizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy. However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient groups who would derive a clear clinical benefit. ASCO/CAP are currently reviewing their guidelines to further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
4. Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions.
- Author
-
Bartlett, John M.S.
- Published
- 2010
- Full Text
- View/download PDF
5. OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.
- Author
-
Francis, Adele, Stein, Robert C., Marshall, Andrea, Rea, Daniel W., Cameron, David A., Macpherson, Iain R., Earl, Helena M., Poole, Christopher J., Hall, Peter S., Bartlett, John M.S., Rooshenas, Leila, Morgan, Adrienne, Harmer, Victoria, Donovan, Jenny, Hulme, Claire, McCabe, Christopher, Pinder, Sarah E., Hughes-Davies, Luke, Makris, Andreas, and Dunn, Janet A.
- Subjects
BREAST cancer patients ,BREAST cancer surgery ,BREAST cancer treatment ,GENE expression ,CANCER chemotherapy - Published
- 2016
- Full Text
- View/download PDF
6. Selecting patients with HER2-low breast cancer: Getting out of the tangle.
- Author
-
Baez-Navarro, Ximena, Salgado, Roberto, Denkert, Carsten, Lennerz, Jochen K., Penault-Llorca, Frédérique, Viale, Giuseppe, Bartlett, John M.S., and van Deurzen, Carolien H.M.
- Subjects
- *
IMMUNOCHEMISTRY , *IMMUNOGLOBULINS , *PATIENT selection , *ONCOGENES , *CANCER patients , *MEDICAL protocols , *BREAST tumors - Abstract
The promising effect of antibody–drug conjugates on breast cancer with low expression of HER2 (HER2-low) raises many questions regarding the optimal selection of patients for this treatment. A key question is whether HER2 immunohistochemistry, an assay optimised to detect HER2 amplification, is reliable enough to assess HER2 protein levels to select patients with HER2-low breast cancer in daily pathology practices worldwide. Moreover, whether this assessment can be performed with sufficient reproducibility between pathologists in daily practices is debatable. Herein, we address the historical track record of the CAP-ASCO HER2 Guidelines, the reported limited reproducibility by pathologists of HER2 immunohistochemistry in the non-amplified cases, and the performance variation of different antibodies. Based on this summary, we propose solutions to improve the robustness to enable reliable identification of patients with HER2-low breast cancer. • The definitions of HER2 0 and 1+ by IHC need to be redefined by the ASCO/CAP. • HER2 IHC assays are not calibrated to detect low-levels of HER2. • Other issues include reproducibility, different HER2-assay performance, etc. • The errors of the PDL1-saga are currently being repeated in the HER2-low narrative. • Solutions are proposed to industry, regulators, and academia (Table 1). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Interactions between MAP kinase and oestrogen receptor in human breast cancer
- Author
-
McGlynn, Liane M., Tovey, Sian, Bartlett, John M.S., Doughty, Julie, Cooke, Timothy G., and Edwards, Joanne
- Subjects
- *
BREAST tumors , *DRUG interactions , *ESTROGEN , *PHOSPHOTRANSFERASES , *DESCRIPTIVE statistics - Abstract
Abstract: Purpose: The oestrogen receptor (ERα) may be activated in a ligand-dependent manner, via oestrogen, or in a ligand-independent manner, via signal transduction pathways. Mitogen Activated Protein Kinase (MAPK) is known to directly phosphorylate ERα at serine 118 in a ligand-independent manner. This study investigated the interaction between MAPK and ERα in breast cancer. Materials & methods: Immunohistochemical experiments were undertaken to determine the expression of MAPK, pMAPK and pER(ser118) in breast tumours to determine their clinical relevance. Immunofluorescent experiments were performed, on MCF-7 breast cancer cells, to monitor the phosphorylation and localisation of MAPK and ERα in response to oestrogen, heregulin and a MAPK inhibitor. Results: Oestrogen and Heregulin stimulated phosphorylation of ERα and its nuclear translocation, but heregulin induced this at levels much lower than those observed with oestrogen. Following stimulation with heregulin, but not oestrogen, treatment with MAPK inhibitor reduced the levels of nuclear pER(ser118). In cells treated with both oestrogen and heregulin, nuclear pER(ser118) was visible; but at levels comparable with heregulin treatment alone. Conclusion: This study confirms that ligand-mediated phosphorylation is associated with rapid nuclear localisation of ERα, due to oestrogen binding. ERα is phosphorylated at serine 118 in a ligand-independent manner. Preventing nuclear translocation of pMAPK reduced the levels of ligand-independent, but not ligand-dependent phosphorylation of ERα. Co-stimulation with both oestrogen and heregulin suggested that heregulin mediated signalling determines the subcellular localisation of ERα. Activation of ERα by direct phosphorylation may result in its rapid deactivation due to degradation or nuclear export. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
- Author
-
Vermeulen, Marijn A., Slaets, Leen, Cardoso, Fatima, Giordano, Sharon H., Tryfonidis, Konstantinos, van Diest, Paul J., Dijkstra, Nizet H., Schröder, Carolien P., van Asperen, Christi J., Linderholm, Barbro, Benstead, Kim, Foekens, Renee, Martens, John W.M., Bartlett, John M.S., and van Deurzen, Carolien H.M.
- Subjects
- *
EPIDERMAL growth factor , *IMMUNOHISTOCHEMISTRY , *LYMPHOCYTES , *PROGNOSIS , *MALE breast cancer - Abstract
Aim Several prognostic histological features have been established in female breast cancer (BC), but it is unknown whether these can be extrapolated to male BC patients. The aim of this study was to evaluate the prognostic value of several histological features in a large series of male BC. Methods Central pathology review was performed for 1483 male BCs collected through part 1 of the European Organisation for Research and Treatment of Cancer (EORTC) International Male BC Program. Pathology review included histological subtype, grade, mitotic activity index (MAI), presence of a fibrotic focus and density of tumour-infiltrating lymphocytes (TILs). These features were correlated with clinical outcome. The relationship between these features and surrogate molecular subtypes using immunohistochemistry was also assessed. Results Median follow-up for overall survival (OS) was 7.1 years. Overall histological grade was not significantly associated with OS (p = 0.129). MAI, the presence of a fibrotic focus and a low TIL density however were correlated with unfavourable OS (p = 0.023, p = 0.004 and p = 0.011, respectively). BC subtype correlated with TIL density (p = 0.015), as we observed a higher density for human epidermal growth factor receptor type 2 (HER2) positive BC compared to luminal HER2-negative subtype. No association was observed between subtype and fibrotic focus. Conclusions Histologic grade was not significantly correlated with clinical outcome in this series, unlike what is seen in female patients. These results contribute to our understanding of male BC and indicate the importance of further research on the optimisation of risk stratification and treatment decisions for male BC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Addressing overtreatment of screen detected DCIS; the LORIS trial.
- Author
-
Francis, Adele, Thomas, Jeremy, Fallowfield, Lesley, Wallis, Matthew, Bartlett, John M.S., Brookes, Cassandra, Roberts, Tracy, Pirrie, Sarah, Gaunt, Claire, Young, Jennie, Billingham, Lucinda, Dodwell, David, Hanby, Andrew, Pinder, Sarah E., Evans, Andrew, Reed, Malcolm, Jenkins, Valerie, Matthews, Lucy, Wilcox, Maggie, and Fairbrother, Patricia
- Subjects
- *
BREAST cancer diagnosis , *BREAST cancer treatment , *DUCTAL carcinoma , *DIAGNOSTIC errors , *RISK assessment , *EARLY detection of cancer , *DIAGNOSIS , *THERAPEUTICS - Abstract
Overdiagnosis, and thus overtreatment, are inevitable consequences of most screening programmes; identification of ways of minimising the impact of overdiagnosis demands new prospective research, in particular the need to separate clinically relevant lesions that require active treatment from those that can be safely left alone or monitored and only need treated if they change characteristics. Breast cancer screening has led to a large increase in ductal carcinoma in situ (DCIS) diagnoses. This is a widely heterogeneous disease and most DCIS detected through screening is of high cytonuclear grade and therefore likely to be important clinically. However, the historic practice of surgical treatment for all DCIS is unlikely to be optimal for lower risk patients. A clearer understanding of how to manage DCIS is required. This article describes the background and development of ‘The low risk’ DCIS trial (LORIS), a phase III trial of surgery versus active monitoring. LORIS will determine if it is appropriate to manage women with screen detected or asymptomatic, low grade and intermediate grade DCIS with low grade features, by active monitoring rather than by surgical treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis.
- Author
-
van de Water, Willemien, Fontein, Duveken B.Y., van Nes, Johanna G.H., Bartlett, John M.S., Hille, Elysée T.M., Putter, Hein, Robson, Tammy, Liefers, Gerrit-Jan, Roumen, Rudi M.H., Seynaeve, Caroline, Dirix, Luc Y., Paridaens, Robert, Kranenbarg, Elma Meershoek-Klein, Nortier, Johan W.R., and van de Velde, Cornelis J.H.
- Published
- 2013
- Full Text
- View/download PDF
11. Impact of Screening and Risk Factors for Local Recurrence and Survival After Conservative Surgery and Radiotherapy for Early Breast Cancer: Results From a Large Series With Long-Term Follow-Up
- Author
-
Kunkler, Ian H., Kerr, Gillian R., Thomas, Jeremy S., Jack, Wilma J.L., Bartlett, John M.S., Pedersen, Hans C., Cameron, David A., Dixon, J. Michael, and Chetty, Udi
- Subjects
- *
CANCER relapse , *FOLLOW-up studies (Medicine) , *BREAST surgery , *CANCER radiotherapy , *IMMUNOHISTOCHEMISTRY , *PROPORTIONAL hazards models , *BREAST cancer treatment - Abstract
Purpose: To investigate conventional prognostic factors for ipsilateral breast tumor recurrence (IBTR), distant metastasis (DM), and survival after breast-conserving therapy (BCT) in screen-detected and symptomatic cases on surveillance up to 25 years. Patients and Methods: A total of 1812 consecutive patients in three cohorts (1981–1989, 1990–1992, and 1993–1998) with T12N01M0 invasive breast cancer were treated with BCT (median follow-up, 14 years). Tumor type and grade were reviewed by a single pathologist. Hormone receptor status was measured by immunohistochemistry on tissue microarrays. A Cox proportional hazards model was used to assess independent prognostic variables for relapse and survival. Results: A total of 205 IBTR occurred, with 5-, 10-, 15-, and 20-year actuarial relapse rates of 4.5% (95% confidence interval [CI] 3.35–5.5%), 8.4% (95% CI 7.1–9.8%), 14.1% (95% CI 12.0–16%), and 17.4% (95% CI 14.5–20.2%). Number of nodes, young age, pathologic tumor size, and multifocality were significant factors for IBTR. Three hundred seventy-eight patients developed DM. The actuarial metastatic rate was 12% at 5 years and 17.9% at 10 years. Young age, number of positive nodes, pathologic tumor size, and tumor grade were significant factors for DM relapse. When conventional prognostic indices were taken into account screen-detected cancers showed no improvement in overall relapse or survival rate compared with symptomatic cases but did show a reduced risk of DM after IBTR. After 10 years IBTR relapse continued at a constant rate of 0.87% per annum. Conclusions: The Edinburgh BCT series has shown that screen-detected invasive breast cancers do not have significantly different clinical outcomes compared with symptomatic cases when pathologic risk factors are taken into account. This suggests that these patients be managed in a similar way. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
12. Association of galectin-3 expression with melanoma progression and prognosis
- Author
-
Brown, Ewan R., Doig, Tamasin, Anderson, Niall, Brenn, Thomas, Doherty, Val, Xu, Yan, Bartlett, John M.S., Smyth, John F., and Melton, David W.
- Subjects
- *
ANALYSIS of variance , *CELL differentiation , *COMPARATIVE studies , *IMMUNOHISTOCHEMISTRY , *MELANOMA , *METAPLASIA , *GENETIC mutation , *NEOVASCULARIZATION , *PROBABILITY theory , *PROGNOSIS , *PROTEINS , *TUMOR markers , *PROPORTIONAL hazards models , *TISSUE arrays - Abstract
Abstract: Aims: Galectin-3 plays an important role in adhesion, proliferation, differentiation, angiogenesis and metastasis in multiple tumours. To investigate the role of galectin-3 in melanoma pathogenesis we examined the expression of galectin-3 in melanocytic lesions and analysed the correlation between galectin-3 expression and clinicopathologic factors including patient survival and BRAF mutation status. Methods: We evaluated the expression of galectin-3 in 53 cases of benign naevi, 31 cases of dysplastic naevi, 59 in-situ melanomas, 314 cases of primary melanoma and 69 metastatic melanomas using tissue microarray and immunohistochemistry. Results: Marked differences in expression of galectin-3 were seen between different categories of melanocytic lesions (ANOVA p <0.0001). An increase in expression of galectin-3 between benign naevi and thin primary melanomas and a progressive decrease in expression between thin primary melanomas and thicker melanomas or metastatic melanomas was seen. Strong galectin-3 expression was associated with improved overall survival (p =0.002 and p =0.0002 for cytoplasmic and nuclear expression, respectively) and melanoma-specific survival (p =0.017 and p =0.003 for cytoplasmic and nuclear expression, respectively). A multifactorial Cox regression analysis suggested that galectin-3 expression was an independent prognostic marker for overall survival in melanoma (risk ratio 0.73, 95% CI 0.547–0.970, p =0.031 for cytoplasmic expression and risk ratio 0.76, 95% CI 0.587–0.985, p =0.036 for nuclear expression). No association between galectin-3 expression and BRAF mutation status was observed. Conclusion: This study suggests that galectin-3 is a marker of progression in melanocytic lesions and a novel prognostic marker in primary melanoma. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
13. Can immune markers help identify fast relapse in patients with muscle invasive bladder cancer?
- Author
-
Olkhov-Mitsel, Ekaterina, Hodgson, Anjelica, Liu, Stanley K., Vesprini, Danny, Bayani, Jane, Bartlett, John M.S., Xu, Bin, and Downes, Michelle R.
- Subjects
- *
BIOMARKERS , *DISEASE relapse , *UROTHELIUM , *BLADDER cancer , *TRANSITIONAL cell carcinoma , *LOG-rank test - Abstract
The aim of this pilot study was to assess the role of immune markers in fast relapse (<2 years) of high-grade muscle invasive urothelial carcinomas of the bladder (HGUC) treated by cystectomy. A series of 40 such cases was investigated for immune protein (CD3, CD4, CD8, CD20, CD68, CD163, FOXP3 and PD-1) status by immunohistochemistry. Decreased expression of all immune cell markers was observed in tumors of patients who relapsed quickly. In Kaplan-Meier (log-rank test) analysis, low CD3, CD4 and CD8 expression was associated with fast relapse (P = 0.005, 0.028, 0.036 respectively). Additional evaluation of the immune transcriptome by NanoString Human PanCancer Immune Panel v.1.1 has identified 5 differentially expressed genes significantly associated with fast relapse. Among these, KLRB1 and HLA-DQA1 were also significant on Kaplan-Meier analysis (log-rank test P = 0.007 and 0.006, respectively). These findings strengthen the potential clinical utility and, hence, the need for further evaluation of immune markers in HGUC prognostication. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. 79: Multi-Parametric Magnetic Resonance Imaging of Multi-Focal Prostate Cancer Unmasks Intra-Prostatic Genomic Heterogeneity and Novel Radio-Genomic Correlates: Results of the Smarter Prostate Interventions and Therapeutics (Spirit) Study.
- Author
-
Correa, Rohann J.M., Aref-Eshghi, Erfan, Alfano, Ryan, Sadikovic, Bekim, Ward, Aaron D., Boutros, Paul C., Bartlett, John M.S., Kassam, Zahra, Chin, Joseph L., Pautler, Stephen E., Gaed, Mena, Gómez, José A., Moussa, Madeleine, and Bauman, Glenn S.
- Subjects
- *
PROSTATE cancer , *PROSTATE , *HETEROGENEITY , *THERAPEUTICS - Published
- 2020
- Full Text
- View/download PDF
15. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases.
- Author
-
Connor, Ashton A., Denroche, Robert E., Jang, Gun Ho, Lemire, Mathieu, Zhang, Amy, Chan-Seng-Yue, Michelle, Wilson, Gavin, Grant, Robert C., Merico, Daniele, Lungu, Ilinca, Bartlett, John M.S., Chadwick, Dianne, Liang, Sheng-Ben, Eagles, Jenna, Mbabaali, Faridah, Miller, Jessica K., Krzyzanowski, Paul, Armstrong, Heather, Luo, Xuemei, and Jorgensen, Lars G.T.
- Subjects
- *
METASTASIS , *CELL cycle , *PATHOLOGY , *GENOMES , *BIOLOGICAL rhythms - Abstract
Summary We integrated clinical, genomic, and transcriptomic data from 224 primaries and 95 metastases from 289 patients to characterize progression of pancreatic ductal adenocarcinoma (PDAC). Driver gene alterations and mutational and expression-based signatures were preserved, with truncations, inversions, and translocations most conserved. Cell cycle progression (CCP) increased with sequential inactivation of tumor suppressors, yet remained higher in metastases, perhaps driven by cell cycle regulatory gene variants. Half of the cases were hypoxic by expression markers, overlapping with molecular subtypes. Paired tumor heterogeneity showed cancer cell migration by Halstedian progression. Multiple PDACs arising synchronously and metachronously in the same pancreas were actually intra-parenchymal metastases, not independent primary tumors. Established clinical co-variates dominated survival analyses, although CCP and hypoxia may inform clinical practice. Graphical Abstract Highlights • Higher cell cycle progression in PDAC metastases; increases with driver gene loss • Half of PDACs are hypoxic and are associated with subtypes and treatment response • Paired tumors show molecular conservation and Halstedian progression • Multiple PDACs arising in the same pancreas are intra-parenchymal metastases Connor et al. molecularly characterize primary and metastatic PDAC and show conserved alterations between primary and metastatic lesions. Clinical features outperform molecular alterations in survival analyses, but cell cycle progression and hypoxia signatures may inform clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.